Patent ID: 7781436

Claim:
A compound of formula I: wherein: R 1 is C 1-6 -alkyl substituted by NR i R ii , —(CH 2 ) m —R a wherein R a is: NR i R ii , or 5 to 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B, or —(CH 2 ) n —(CO)—R b or —(CH 2 ) n —(SO 2 )—R b , wherein R b is: C 1-6 -alkyl, C 1-6 -alkoxy, NR i R ii , or 5 to 6 membered-heterocycloalkyl, aryl, or 5 or 6 membered heteroaryl each of which is optionally substituted by one or more B, or R 1 and R 3 together with the indole ring to which they are attached form a piperazinyl, which is optionally substituted by ═O, C(O)O—C 1-6 -alkyl or C 1-6 -alkyl; there is one or more R 2 , wherein each R 2 is the same or different, R 2 is one or more H, halo, or C 1-6 -alkyl; R 3 is H, or C 1-6 -alkyl; A is wherein R 4 is aryl selected from the group consisting of phenyl, naphthyl, phenanthryl, fluorenyl, indenyl, pentalenyl, azulenyl, biphenyl, aminodiphenyl, diphenylsulfidyl, diphenylsulfonyl, and diphenylisopropylidenyl, 5 or 6 membered heteroaryl selected from the group consisting of imidazolyl, oxazolyl, thiazolyl, pyrazinyl, pyrrolyl, pyrazinyl, pyridinyl, pyrimidinyl, and furanyl, or a 9 or 10-membered bicyclic heteroaryl ring selected from the group consisting of indolyl, thieno[2,3-c]pyridinyl, thieno[3,2-c]pyridinyl, benzoxazolyl, and benzisoxazolyl, each of which is optionally substituted by halo, C 1-6 -alkyl, C 1-6 -alkoxy, C 1-6 -haloalkyl, nitro, hydroxyl, or C 1-6 -haloalkoxy, or by an oxo or dioxo bridge; R 5 is H, OH, or CN; B is halo, C 1-6 -alkyl optionally substituted by CN, halo or C 1-6 -alkoxy, or C 1-6 -alkoxy; R i and R ii are each independently H, C 1-6 -alkyl, C 1-6 -alkyl-NR iii R iv , —C(O)—C 1-6 -alkyl or —S(O) 2 —C 1-6 -alkyl; R iii and R iv are each independently H or C 1-6 -alkyl; m is 1 to 6; and n is 0 to 4; wherein; 5 or 6 membered heteroaryl is selected from the group consisting of oxazolyl, thiazolyl, pyrazinyl, pyrrolyl, pyridinyl, pyrimidinyl, and furanyl; and an oxo or dioxo bridge is selected from the group consisting of or a pharmaceutically acceptable salt thereof.